Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

Inclusion Criteria: * Subject has NSCLC with a histologically confirmed diagnosis of adenocarcinoma with measurable disease (stage IIIB, with malignant pleural effusion, and stage IV) and either has a demonstrated activating mutation of the EGF receptor in tumor tissue or meets one of three criteria: asian, female, and minimal or no smoking history. * Measurable disease defined according to RECIST * ECOG performance status of 0 or 1 * Normal organ and marrow function * No other malignancies within 5 years, except for non-melanoma skin cancer Exclusion Criteria: * Radiation to ≥25% of bone marrow within 30 days of XL647 treatment * Prior systemic anticancer therapy, including cytotoxic chemotherapy, anti-VEGF, anti-VEGFR, or anti-EGFR agents or investigational drug * Subject has not recovered to ≤ grade 1 or to within 10% of baseline values from adverse events due to other medications administered \> 30 days before study enrollment * Receiving anticoagulation therapy with warfarin (low-dose warfarin \< 1 mg/day, heparin and low molecular weight heparins are permitted) * The subject meets any of the following cardiac criteria: * Corrected QT interval (QTc) of \> 460 msec * Family history of congenital long QT syndrome or unexplained sudden death * History of sustained ventricular arrhythmias * Has a finding of left bundle branch block * Has an obligate pacemaker * Has important bradycardia defined as a heart rate of \< 50 bpm due to sinus node dysfunction * Has uncontrolled hypertension * Has symptomatic congestive heart failure, unstable angina, or a myocardial infarction within the past 3 months * Has a serum potassium or serum magnesium level that falls outside the normal range * The subject has progressive symptomatic or hemorrhagic brain or leptomeningeal metastases * Uncontrolled intercurrent illness * Subject is pregnant or breastfeeding * Known HIV